SCHEMBL1104955

SCHEMBL1104955

CCBOc1ccc(S(=O)(=O)NC)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.59
LMNA P02545 3/20 0.59
HTT P42858 1/20 0.59
ALDH1A1 P00352 4/20 0.49
GAA P10253 1/20 0.48
CA1 P00915 3/20 0.47
CA2 P00918 3/20 0.47
CA12 O43570 2/20 0.47
CA3 P07451 2/20 0.47
CA4 P22748 2/20 0.47
CA6 P23280 2/20 0.47
CA5A P35218 2/20 0.47
CA7 P43166 2/20 0.47
CA9 Q16790 2/20 0.47
CA13 Q8N1Q1 2/20 0.47
CA14 Q9ULX7 2/20 0.47
CA5B Q9Y2D0 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.42
PKM P14618 2/20 0.40
NR3C2 P08235 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4050348 0.82 SMN1; SMN2 (0.68) SMN1; SMN2LMNAHTTALDH1A1GAA
SCHEMBL1104964 0.79 CA2 (0.59) SMN1; SMN2HTTALDH1A1CA1CA2
SCHEMBL1104957 0.79 ALDH1A1 (0.39) SMN1; SMN2LMNAHTTALDH1A1GAA
SCHEMBL15963707 0.77 ALDH1A1 (0.71) SMN1; SMN2LMNAHTTALDH1A1GAA
SCHEMBL1104972 0.76 LMNA (0.59) SMN1; SMN2LMNAHTTALDH1A1L3MBTL1
SCHEMBL17907417 0.75 SMN1; SMN2 (1.00) SMN1; SMN2LMNAHTTALDH1A1GAA
SCHEMBL1104965 0.74 POLB (0.69) SMN1; SMN2LMNAALDH1A1GAAMAPK1
SCHEMBL7629070 0.74 SMN1; SMN2 (0.80) SMN1; SMN2LMNAHTTALDH1A1GAA
SCHEMBL6846126 0.74 TSHR (0.64) SMN1; SMN2LMNAHTTALDH1A1CA1
SCHEMBL1620820 0.74 SMN1; SMN2 (0.73) SMN1; SMN2LMNAHTTALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8907101-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2014-12-09 US disclosed
US-8153814-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2012-04-10 US disclosed
US-20100197655-A1 SULFONAMIDE DERIVATIVES Pfizer Limited Icagen, Inc. 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197655-A1 SULFONAMIDE DERIVATIVES SULT2A1, SULT1A1, TPST2 SMN1; SMN2 86/4885LMNA 2523/4885HTT 661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.